Login to Your Account

So long, Sollpura: Anthera sacks lead program after dismal 'RESULT'

By Marie Powers
News Editor

Tuesday, March 13, 2018

Anthera Pharmaceuticals Inc. reported disastrous results from phase III RESULT study of Sollpura (liprotamase), which failed to reach the noninferiority margin of the coefficient of fat absorption (CFA) primary endpoint in individuals with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (CNA), which measures protein absorption.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription